预约演示
Prevduo, a Neostigmine-Glycopyrrolate Combo Product, Now Available
2024-02-18
Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection) has been made available by Endo for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBA) after surgery, while decreasing the peripheral muscarinic effects (eg, bradycardia and excessive secretions) associated with cholinesterase inhibition following NMBA reversal administration.
Prevduo contains a fixed-dose combination of neostigmine, a cholinesterase inhibitor and glycopyrrolate, an antimuscarinic agent. Both drugs have been previously approved as single agent products; the new combination removes the need for 2 syringe preparations and administrations.
“This is the latest way we’re addressing operational and clinical challenges in order to support patient care,” said Scott Sims, Senior Vice President and General Manager, Injectable Solutions & Generics at Endo. “With 2 medications in one ready-to-use syringe, Prevduo reduces complexity and increases efficiency for hospitals and health care providers.”
Prevduo is supplied as a solution containing 3mg/3mL of neostigmine methylsulfate and 0.6mg/3mL of glycopyrrolate (1mg/mL of neostigmine methylsulfate and 0.2mg/mL of glycopyrrolate) in a single-dose 3mL prefilled syringe. The product will be distributed in the US by Slayback Pharma LLC.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
-提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。